Chimeric Therapeutics Begins Phase 1/2 Clinical Trial for CHM CDH17 Cell Therapy
CHM (CHM) Share Update July 2024 Monday 22nd
Chimeric Therapeutics Enrolls First Patient in Phase 1/2 Clinical Trial
Chimeric Therapeutics (ASX:CHM) has announced a significant milestone in its quest to advance cancer treatment. The company has enrolled the first patient in its Phase 1/2 clinical trial for CHM CDH17 cell therapy, aimed at treating advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.
Instant Summary:
- First patient enrolled in CHM CDH17 Phase 1/2 clinical trial.
- Trial aims to determine recommended Phase 2 dose and evaluate safety and response rate.
- Focus on advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.
- Additional trial sites expected to open in the second half of 2024.
Clinical Trial Details
The Phase 1/2 trial, identified as NCT06055439, is a two-stage study designed to determine the recommended Phase 2 dose of CHM CDH17 and to evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.
Dr. Rebecca McQualter, Chief Operating Officer of Chimeric Therapeutics, expressed her excitement about this milestone, stating, 'This is great progress for this first-in-human study for bowel cancer patients with significant unmet need; congratulations to the CHM team and our investigational sites on this milestone.'
Professor Xianxin Hua from Penn's Perelman School of Medicine also highlighted the importance of this development, saying, 'It is exciting to see the advancement from the development of the CDH17 CAR T technology in our laboratory to the enrollment of the first patient in this Phase 1/2 study.'
Future Plans
Chimeric Therapeutics plans to open additional clinical trial sites in the second half of 2024, further expanding the reach and potential impact of this groundbreaking study.
About Chimeric Therapeutics
Chimeric Therapeutics is a clinical-stage cell therapy company based in Australia. The company is focused on bringing the promise of cell therapy to life for more patients with cancer. Their diversified portfolio includes first-in-class autologous CAR T cell therapies and best-in-class allogeneic NK cell therapies.
CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T therapy invented at the University of Pennsylvania. Preclinical evidence published in March 2022 in Nature Cancer demonstrated complete eradication of tumors in seven types of cancer. The therapy is currently in preclinical development with plans for a Phase 1A clinical trial in gastrointestinal and neuroendocrine tumors in 2024.
Other promising therapies in Chimeric's pipeline include CHM CLTX, a CAR T therapy for solid tumors, and CHM CORE-NK, an off-the-shelf NK cell therapy. Both therapies have shown positive preliminary data in early clinical trials.
The enrollment of the first patient in the CHM CDH17 Phase 1/2 clinical trial is a significant step forward for Chimeric Therapeutics. This milestone could boost investor confidence and positively impact the company's stock price. The potential success of this trial could also have broader implications for the cell therapy market, particularly in the treatment of advanced cancers.
Investor Reaction:
Investors and analysts have reacted positively to the news, with many expressing optimism about the potential of CHM CDH17 to address unmet needs in cancer treatment. The announcement has been seen as a validation of Chimeric's innovative approach to cell therapy.
Conclusion:
Investors should keep a close eye on the progress of the CHM CDH17 Phase 1/2 clinical trial and the opening of additional trial sites. The success of this trial could significantly impact Chimeric Therapeutics' position in the market and its long-term growth potential. As always, staying informed and monitoring developments is crucial for making well-informed investment decisions.